论文部分内容阅读
62例高血压患者与27例年龄相匹配的健康对照者,同步测定血浆心钠素、血清及红细胞镁含量。结果Ⅰ期高血压患者血浆心钠素及红细胞镁含量与正常组比较无明显差异,Ⅱ、Ⅲ期患者血浆心钠素浓度明显高于正常组,各期高血压患者间心钠素均值差异显著（P<0.001）,提示高血压越严重心钠素水平越高。Ⅱ、Ⅲ期高血压组红细胞镁含量降低显著（P<0.001）,表明红细胞镁测定对Ⅱ、Ⅲ期患者有临床意义。各组间血清镁与正常组比较无显著变化。认为高血压患者存在细胞膜的阳离子转化障碍。Ⅱ、Ⅲ期患者血浆心钠素增高与红细胞镁降低呈负相关（-0.4,-0.72,P<000.1）。Ⅱ、Ⅲ高血压适合镁剂及促进镁向细胞内转移的药物治疗。
62 patients with hypertension and 27 age-matched healthy controls, simultaneous determination of plasma atrial natriuretic peptide, serum and erythrocyte magnesium content. Results There was no significant difference in the plasma levels of atrial natriuretic peptide and erythrocyte magnesium in patients with stage Ⅰ hypertension. The plasma atrial natriuretic peptide concentrations in patients with stage Ⅱ and Ⅲ were significantly higher than those in normal controls (P <0.001), suggesting that the more severe hypertension, the higher the level of atrial natriuretic peptide. The levels of erythrocyte magnesium in group Ⅱ and Ⅲ were significantly lower (P <0.001), indicating that the determination of erythrocyte magnesium has clinical significance in patients with stage Ⅱ and Ⅲ. There was no significant change in serum magnesium between the two groups compared with the normal group. Hypertensive patients believe that there is a cell membrane cation conversion disorders. Plasma levels of atrial natriuretic peptide in patients with stage II and III were negatively correlated with decreased erythrocyte magnesium (-0.4, -0.72, P <000.1). Ⅱ, Ⅲ high blood pressure suitable for magnesium and magnesium to promote intracellular metastasis of drug treatment.